The three manufacturing sites specialize in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana, US). Eli Lilly, facing challenges with the ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

The analysts valued the Alzheimer’s market across the U.S., France, Germany, Italy, Spain ... Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly’s (NYSE:LLY) new cancer therapy ... share with about $3B in sales by 2032 in the U.S., France, Germany, Italy, Spain, the U.K., and Japan. In January last year, Lilly (LLY) received ...